Statistics for HLS Therapeutics Inc (id:13657 HLS)

Valuation metrics

Market cap

100.47M

Enterprise value

213.35M

Trailing P/E (ttm)

-3.89

Forward P/E

-6.32

PEG ratio

-6.32

Price/Sales (ttm)

1.76

Price/Book (mrq)

1.27

Enterprise Value/Revenue

2.67

Enterprise Value/EBITDA

9.65

Overview

Shares outstanding

31.79M

Float

19.29M

Shares short

4.70K

% Held by insiders

0.00%

% Held by institutions

0.65%

Average volume (10 days)

28.01K

Average volume (90 days)

Price summary

52-Week low

3.00

52-Week high

5.48

52-Week change

-7.25%

Beta

1.07

50-Day moving average

3.54

200-Day moving average

3.78

Dividends and splits

Forward annual dividend rate

0.20

Forward annual dividend yield

0.06

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

1.73

Payout ratio

0.00

Dividend date

June 15th, 2023

Ex-dividend date

April 27th, 2023

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-38.70%

Operating margin

-13.44%

Operational effectiveness

Return on assets

-2.74%

Return on equity

-24.33%

Income statement

Revenue (ttm)

1.78

Revenue per share (ttm)

1.78

Quarterly revenue growth (yoy)

Gross profit (ttm)

55.45M

EBITDA

19.07M

Net income to common (ttm)

-30,889,164.00

Diluted EPS (ttm)

-0.97

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

24.59M

Total cash per share (mrq)

0.55

Total debt (mrq)

96.20M

Total Debt/Equity (mrq)

86.50

Current ratio (mrq)

156.00%

Book value per share (mrq)

2.50

Cash flow

Cash flow statement

11.96M

Levered free cash flow (LFCF)

38.13M